GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ginkgo Bioworks Holdings
Shares of Ginkgo Bioworks, a synthetic biology platform, are a venture bet on the "bio-revolution." Their price reflects not current revenues, but investors' belief in the long-term potential of programming cells to create new products in pharmaceuticals, agriculture, and industrial applications.
Share prices of companies in the market segment - AI
Ginkgo Bioworks positions itself as an "organism engineering" company, using its cell programming platform across various industries. We've categorized it as "AI" (synthetic biology). The chart below shows how the market values this futuristic and capital-intensive sector.
Broad Market Index - GURU.Markets
Ginkgo Bioworks positions itself as an "organism-engineering" company, using its cell programming platform across a variety of industries. Its futuristic nature earns it a spot in the GURU.Markets index. The chart below compares its performance to the overall market.
Change in the price of a company, segment, and market as a whole per day
DNA - Daily change in the company's share price Ginkgo Bioworks Holdings
For Ginkgo Bioworks, a cell programming platform, change_co is a measure of speculative volatility. Daily fluctuations reflect not current profits, but rather investors' faith in the future of synthetic biology. This metric is important for analyzing innovative but high-risk companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - AI
Ginkgo Bioworks Holdings, Inc. is a leading synthetic biology platform. This chart illustrates the extreme volatility of the biotech sector. Comparison with DNA, a bet on the future of "cell programming," helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Ginkgo Bioworks is a biotech company that positions itself as an "organism engineer," creating microorganisms for various industries. This is a cutting-edge and highly speculative field of biotech. The chart below illustrates the high volatility typical of this sector, reflecting Ginkgo's risks and potential.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ginkgo Bioworks Holdings
Ginkgo, a "company that programs organisms," has been proving the viability of its synthetic biology platform to the market over the past year. Its year-over-year share price performance, shown in the chart, reflects its success in securing major partnerships and improving its biosafety.
Annual dynamics of market capitalization of the market segment - AI
Ginkgo Bioworks Holdings is a leading company in the field of synthetic biology. Its platform enables the "programming" of cells for various applications, from pharmaceuticals to agriculture. Its stock price is extremely volatile, reflecting investors' faith in its long-term potential rather than its current profitability.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ginkgo, with its platform for "programming" cells, is one of the most ambitious and speculative stories on the market. Its stock price is completely unrelated to the economy. Its chart reflects investors' belief that synthetic biology will revolutionize everything from medicine to industry.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ginkgo Bioworks Holdings
Lincoln Educational, a provider of vocational education. The monthly fluctuations on the chart reflect the number of students. Demand for skilled workers in industries such as auto repair and healthcare is also a significant factor influencing its revenue.
Monthly dynamics of market capitalization of the market segment - AI
Ginkgo Bioworks is at the forefront of synthetic biology, programming cells to solve global challenges. The biotech sector, whose dynamics you see on the chart, is buzzing with anticipation of breakthroughs. Ginkgo's story is a bet that its platform will become the industry standard, and its trajectory will reveal how much investors believe in this biological revolution.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ginkgo Bioworks calls itself an "organism company," using AI and automation to program cells on demand. Its business is a bet on the future of synthetic biology. The broader market chart reflects risk appetite, making it interesting to see how this futuristic platform's shares have responded to overall market sentiment and its own scientific milestones.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ginkgo Bioworks Holdings
Ginkgo Bioworks, which markets itself as an "organism engineer," has a highly volatile stock. Weekly performance is driven by news of partnerships with companies across various industries, from pharmaceuticals to agriculture, and general interest in synthetic biology.
Weekly dynamics of market capitalization of the market segment - AI
Ginkgo Bioworks is a synthetic biology platform. Comparing its weekly performance with the biotech sector reveals the uniqueness of its business model. The chart shows how news of partnerships with companies from various industries drives its stock price movement differently than that of traditional R&D companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Ginkgo, a synthetic biology platform, live in a world of their own. Their performance is driven by news of partnerships. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
DNA - Market capitalization of the company Ginkgo Bioworks Holdings
Ginkgo Bioworks' market capitalization chart is one of the most ambitious stories in biotech. The company positions itself as a "cell programming platform." Its sharp decline after its SPAC IPO reflects investor skepticism and the difficulty of valuing this unique, yet unprofitable, business model.
DNA - Share of the company's market capitalization Ginkgo Bioworks Holdings within the market segment - AI
Ginkgo Bioworks calls itself a "cell programming company," creating custom microorganisms for industries ranging from pharmaceuticals to agriculture. Its stake in the sector is a bet on a future where biology becomes programmable. The chart below shows the market's weighting for this ambitious synthetic biology platform.
Market capitalization of the market segment - AI
Ginkgo Bioworks positions itself as an "organism company," providing a platform for programming cells for various industries, from pharmaceuticals to agriculture. The chart below shows the overall market capitalization of the AI sector. It reflects the enormous, yet still largely speculative, expectations for synthetic biology.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents a "factory" for programming organisms. Ginkgo Bioworks uses robotics and AI to engineer microbes that can produce everything from flavors to drugs. Its volatile line is a bet that synthetic biology will become one of the key technologies of the 21st century.
Book value capitalization of the company, segment and market as a whole
DNA - Book value capitalization of the company Ginkgo Bioworks Holdings
Ginkgo Bioworks' book value is derived from its automated cell-programming laboratories ("foundries") and its vast financial reserves. This is capital built at the intersection of biology and engineering. The chart shows how the company, a pioneer in synthetic biology, accumulated and spent resources to create its unique platform.
DNA - Share of the company's book capitalization Ginkgo Bioworks Holdings within the market segment - AI
Ginkgo Bioworks is an "organism engineering" company. It doesn't manufacture finished products, but rather designs microbes for other companies. Its "factories" are highly automated laboratories (foundries). The chart shows the company's share of this unique and cutting-edge biotech infrastructure.
Market segment balance sheet capitalization - AI
Synthetic biology, the practice pursued by Ginkgo Bioworks, has a unique model. It's "lighter" than pharmaceutical companies, as it doesn't bring drugs to market, but it does require capital-intensive "foundries"—highly automated labs for programming cells. This makes it a technological heavyweight.
Book value of all companies included in the broad market index - GURU.Markets
Ginkgo Bioworks' assets are not drugs, but rather massive automated laboratories ("biofactories") where robots and AI are used to engineer microorganisms for various industries, from pharmaceuticals to agriculture. The book value reflects the physical scale of this unique synthetic biology platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ginkgo Bioworks Holdings
Ginkgo Bioworks, the "organism factory," is valued by the market at multiples of the value of its automated laboratories. Investors are paying for its unique synthetic biology platform and its potential to revolutionize numerous industries, from pharmaceuticals to agriculture.
Market to book capitalization ratio in a market segment - AI
Ginkgo Bioworks positions itself as an "organism-as-company," providing a platform for programming cells for various needs. Its value lies in its technology. The chart shows the colossal premium investors are paying for its vision of the future of biotech, despite its current losses.
Market to book capitalization ratio for the market as a whole
Ginkgo Bioworks positions itself as an "organism engineering" company. It uses its cell programming platform for a variety of clients, from pharmaceuticals to agriculture. Its value lies in this platform. This metric reflects how the market values this unique "horizontal platform" business model in biotechnology.
Debts of the company, segment and market as a whole
DNA - Company debts Ginkgo Bioworks Holdings
Ginkgo Bioworks, a cellular programming platform, has an ambitious and capital-intensive business model. The company finances its operations and numerous acquisitions with a massive amount of capital raised during its IPO, avoiding traditional debt. This chart reflects its unique equity-based growth strategy.
Market segment debts - AI
Ginkgo Bioworks positions itself as an "organism engineering" company, using its platform to program cells for clients across industries, from pharmaceuticals to agriculture. This business model is capital-intensive and requires significant investment in R&D. The chart below shows how the company funds its ambitious and futuristic scientific platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ginkgo Bioworks Holdings
Ginkgo Bioworks positions itself as an "organism engineering" company, using its platform to program cells for clients across various industries. Developing such a complex biotech platform requires colossal investments in R&D and equipment. This chart shows how the company uses debt to finance its ambitious and capital-intensive operations.
Market segment debt to market segment book capitalization - AI
Ginkgo Bioworks positions itself as a "cell programming company," providing a synthetic biology platform for various industries. It's a highly capital-intensive business with a long-term outlook. This chart shows how the company finances its ambitious scientific platform, comparing its debt to the market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
Ginkgo Bioworks positions itself as an "organism company," creating a platform for programming cells. This is a groundbreaking but highly capital-intensive area of synthetic biology. How heavily does Ginkgo rely on debt to finance its futuristic R&D platform? This chart of total market debt helps assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - Ginkgo Bioworks Holdings
Ginkgo Bioworks is a biotech company that positions itself as a platform for "programming" cells. This chart shows how investors view its unique business model. Its high and volatile valuation reflects both faith in the enormous potential of synthetic biology and skepticism about its current profitability.
P/E of the market segment - AI
Ginkgo Bioworks positions itself as a "company that programs cells." It uses advanced robotics and data analytics to develop and produce microorganisms for various industries, from pharmaceuticals to agriculture. This chart shows the average rating for the AI sector, helping to understand how the market values this unique biotech platform.
P/E of the market as a whole
Ginkgo Bioworks positions itself as an "organism-engineering" company, creating custom microbes for various industries. It's a disruptive, yet speculative, business model. Does its valuation reflect the general investor appetite for risky future technologies, or does it reflect a unique belief in its platform and its potential to transform industry?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ginkgo Bioworks Holdings
Ginkgo Bioworks positions itself as an "organism-engineering" company. It uses synthetic biology and AI to program cells for clients across various industries. This chart reflects investors' confidence in the long-term potential of this platform. Future profits depend on the success of its projects and the transition to recurring revenue.
%20P%2FE%20Ginkgo%20Bioworks%20Holdings&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ginkgo-Bioworks-Holdings&v=1772635574932 "Chart of the company's future (projected) P/E Ginkgo Bioworks Holdings")
Future (projected) P/E of the market segment - AI
Ginkgo Bioworks positions itself as an "organism company," providing a cell programming platform for clients across industries, from pharmaceuticals to agriculture. This is a unique business model in the field of synthetic biology. The chart reflects sector expectations. Comparisons help understand the market's confidence in Ginkgo's long-term vision and platform approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-AI&v=1772635574969 "Future (projected) P/E graph of the market segment - AI")
Future (projected) P/E of the market as a whole
Ginkgo Bioworks Holdings operates a cell programming platform, essentially serving as a biotech foundry. It's a unique business model based on the future of the "bioeconomy." This chart shows the market's willingness to invest in platform companies whose full value will be realized in the long term.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772635574978 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ginkgo Bioworks Holdings
Ginkgo Bioworks provides a cellular programming platform, enabling other companies to develop new products in pharmaceuticals, agriculture, and industrial applications. Its business model is similar to "AWS for biotech." This chart shows how the company is investing in its platform, aiming to monetize the synthetic biology revolution.
Profit of companies in the market segment - AI
Ginkgo Bioworks positions itself as an "organism-engineering" company, using its platform to program cells for clients across various industries. This AI profitability chart reflects its belief in the potential of synthetic biology. Their business model is based on creating a platform that will accelerate innovation in pharmaceuticals, agriculture, and manufacturing.
Overall market profit
Ginkgo Bioworks positions itself as an "organism company," offering a cell programming platform for industries ranging from pharmaceuticals to agriculture. It's a revolutionary business model. Growing corporate profits, as shown in this graph, encourage companies to invest in research and development, creating demand for Ginkgo's innovative biotech solutions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ginkgo Bioworks Holdings
Ginkgo Bioworks positions itself as an "organism-engineering" company. It uses robotics and data analysis to program cells for clients across industries, from pharmaceuticals to agriculture. This graph reflects analysts' expectations for an increase in the number of projects and a shift from services to royalty revenue from successful products.
%20profit%20of%20the%20company%20Ginkgo%20Bioworks%20Holdings&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ginkgo-Bioworks-Holdings&v=1772635574987 "Graph of future (projected) profit of the company Ginkgo Bioworks Holdings")
Future (predicted) profit of companies in the market segment - AI
Ginkgo Bioworks positions itself as an "organism company," providing a cellular programming platform for industries ranging from pharmaceuticals to agriculture. Its success depends on the widespread adoption of synthetic biology. This biotech chart reflects the market's belief that biotechnology will be a key driver of innovation in the coming decades.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-AI&v=1772635574989 "Graph of future (predicted) profits of companies in a market segment - AI")
Future (predicted) profit of the market as a whole
Ginkgo Bioworks positions itself as an "organism-as-company," programming cells for various purposes, from industrial to medical. Its business lies at the intersection of biotech and AI. The overall economic outlook, reflected in this chart, influences its partners' willingness to invest in long-term, capital-intensive R&D projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772635574990 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ginkgo Bioworks Holdings
Ginkgo Bioworks is involved in synthetic biology, programming cells for various applications, from pharmaceuticals to agriculture. This chart is crucial because it shows the huge premium investors are paying for its revenue. It's a bet on a future where bioengineering will become a key technology, and on Ginkgo's leadership in this revolution.
P/S market segment - AI
Ginkgo Bioworks positions itself as an "organism-as-company," using synthetic biology to program cells for clients across industries, from pharmaceuticals to agriculture. Revenue is generated from services and royalties. This chart helps understand how investors evaluate this disruptive and complex business model, based on the future potential of biotechnology.
P/S of the market as a whole
Ginkgo Bioworks positions itself as an "organism engineering" company. It uses automation and data analysis to program cells for a variety of applications, from pharmaceuticals to agriculture. This chart, which reflects revenue estimates for traditional businesses, highlights Ginkgo's valuation as a platform with enormous potential to transform entire industries.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ginkgo Bioworks Holdings
Ginkgo Bioworks positions itself as a "cell programming company." It uses synthetic biology to create microorganisms for a variety of industries, from pharmaceuticals to agriculture. This chart reflects investors' confidence in the long-term potential of its platform and future revenue from royalties and successful projects.
%20P%2FS%20Ginkgo%20Bioworks%20Holdings&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ginkgo-Bioworks-Holdings&v=1772635575013 "The graph of the company's future (projected) P/S Ginkgo Bioworks Holdings")
Future (projected) P/S of the market segment - AI
Ginkgo Bioworks Holdings operates a cellular programming platform using synthetic biology to create microorganisms with targeted properties for various industries, from pharmaceuticals to agriculture. This chart shows the average estimated future sales in the biotech and AI sector. It helps understand how the market views Ginkgo's long-term potential.
%20P%2FS%20market%20segment%20graph%20-%20AI&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-AI&v=1772635575020 "Future (projected) P/S market segment graph - AI")
Future (projected) P/S of the market as a whole
Ginkgo Bioworks positions itself as an "organism-engineering" company. It uses robotics and AI to engineer microorganisms for a variety of industries, from pharmaceuticals to agriculture. This chart shows investor revenue growth expectations. Ginkgo's business is at the forefront of synthetic biology, promising to revolutionize many sectors of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772635575031 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ginkgo Bioworks Holdings
This chart shows the revenue of Ginkgo Bioworks, a company that operates a synthetic biology platform. It programs cells for various applications, from flavor production to drug development. Revenue is generated from development services and royalties. The dynamics reflect the demand for biotech solutions across a wide range of economic sectors.
Sales of companies in the market segment - AI
Ginkgo Bioworks Holdings uses a cutting-edge platform to program cells, similar to how computers are programmed. The company helps partners in pharmaceuticals, agriculture, and industry create new products. This chart reflects the growth of the synthetic biology market. Ginkgo is a pioneer, and its technologies have the potential to revolutionize the way we produce virtually everything.
Overall market sales
Ginkgo Bioworks provides a cellular programming platform used in industries ranging from pharmaceuticals to agriculture. Demand for its services is driven by biotechnology investment. This total revenue chart reflects the state of the economy, which impacts companies' R&D budgets and their willingness to innovate.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ginkgo Bioworks Holdings
Ginkgo Bioworks positions itself as an "organism company," using synthetic biology to program cells for clients across various industries. Future revenue depends on the success of its platform. The chart reflects analyst expectations for the commercialization of this cutting-edge technology.
%20sales%20of%20the%20company%20Ginkgo%20Bioworks%20Holdings&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ginkgo-Bioworks-Holdings&v=1772635575072 "Schedule of future (projected) sales of the company Ginkgo Bioworks Holdings")
Future (projected) sales of companies in the market segment - AI
Ginkgo Bioworks positions itself as an "organism company," using its microbial engineering platform for clients in industries ranging from pharmaceuticals to agriculture. This unique business model bridges biology and technology. This graph shows the forecast for the entire biotech industry, where Ginkgo is a pioneer in synthetic biology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-AI&v=1772635575082 "Schedule of future (projected) sales of companies in the market segment - AI")
Future (projected) sales of the market as a whole
Ginkgo Bioworks positions itself as an "organism company," providing a cellular programming platform for industries ranging from pharmaceuticals to agriculture. Its business is a bet on the future of the bioeconomy. This chart reflects the current market situation, while Ginkgo's contracts and partnerships are a leading indicator of how biotech will transform industry.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772635575092 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ginkgo Bioworks Holdings
Ginkgo Bioworks positions itself as an "organism engineering" company, creating custom microorganisms for various industries, from pharmaceuticals to agriculture. The profitability of its unique business model depends on the success of its R&D projects. This chart shows the significant investment in creating a platform that has the potential to transform entire industries.
Market segment marginality - AI
Ginkgo Bioworks positions itself as an "organism company," providing a synthetic biology platform that other companies use to develop new products, from flavors to drugs. The profitability of their unique business model depends on the success of their clients' projects. This chart shows their operating results. The industry comparison highlights their platform approach to biotech.
Market marginality as a whole
Ginkgo Bioworks positions itself as an "organism-as-company," providing a platform for programming cells for various purposes, from flavor production to drug development. This chart, reflecting the traditional economy, is just the backdrop for them. Ginkgo is betting on the future "bioeconomy," and their success depends on technological breakthroughs and the ability of their platform to solve their clients' problems.
Employees in the company, segment and market as a whole
Number of employees in the company Ginkgo Bioworks Holdings
Ginkgo Bioworks operates a cellular programming platform, essentially serving as a biotech foundry. Its large and growing staff consists of scientists and engineers working to automate biological research. This chart reflects the scaling of its unique R&D platform.
Share of the company's employees Ginkgo Bioworks Holdings within the market segment - AI
Ginkgo Bioworks positions itself as an "organism-as-company," using synthetic biology to program cells for clients across various industries. This chart shows the unique scientific talent the company attracts. Behind it lies a large team of biologists and engineers working in automated labs to create innovative products.
Number of employees in the market segment - AI
Ginkgo Bioworks Holdings is a leading platform for cellular programming and synthetic biology, serving clients across industries from pharmaceuticals to agriculture. This chart shows the dynamics of employment at the forefront of biotechnology. The exponential growth of scientists and engineers reflects the company's revolutionary potential for creating microorganisms for specific applications.
Number of employees in the market as a whole
Ginkgo Bioworks positions itself as an "organism-as-company," providing a platform for biologically programming cells. Its clients use this platform to develop new products in pharmaceuticals, agriculture, and industrial applications. This metric reflects how the synthetic biology Ginkgo is developing is creating an entirely new industry and jobs at the intersection of biology and IT.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ginkgo Bioworks Holdings (DNA)
Ginkgo Bioworks positions itself as an "organism engineer," using automated labs (foundries) and AI to program cells. This chart is a prime example of intellectual capital valuation. The value is in the platform, not the people. The chart shows how highly the market values this scalable technology platform (foundry and codebase) per employee.
%20of%20the%20company%20Ginkgo%20Bioworks%20Holdings%20(DNA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ginkgo-Bioworks-Holdings-DNA&v=1772635575176 "Chart of market capitalization per employee (in thousands of dollars) of the company Ginkgo Bioworks Holdings (DNA)")
Market capitalization per employee (in thousands of dollars) in the market segment - AI
Ginkgo Bioworks positions itself as an "organism-engineering" company, using biotechnology to program cells for clients across various industries. Its value lies in its unique platform and technologies. This chart demonstrates the market's high appreciation for its innovative business model, where the primary value is generated by intellectual property.
%20by%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-AI&v=1772635575190 "Market capitalization per employee (in thousands of dollars) by market segment - AI")
Market capitalization per employee (in thousands of dollars) for the overall market
Ginkgo Bioworks positions itself as an "organism-engineering" company, using its platform to custom-program cells for various industries. This chart shows how the market values its unique biotech business model. The high cost per employee reflects the value of its automated lab and genetic code library.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772635575197 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ginkgo Bioworks Holdings (DNA)
Ginkgo Bioworks positions itself as an "organism engineer." They use AI, robotics, and synthetic biology to "program" cells (yeast, bacteria) to produce desired substances (flavorings, drugs). This is an R&D platform. This chart shows the cost of their "factory": huge investments in technology and PhD specialists per employee.
%20Chart%20Ginkgo%20Bioworks%20Holdings%20(DNA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ginkgo-Bioworks-Holdings-DNA&v=1772635575200 "Company Profit Per Employee (in thousands of dollars) Chart Ginkgo Bioworks Holdings (DNA)")
Profit per employee (in thousands of dollars) in the market segment - AI
Ginkgo Bioworks (DNA) is a synthetic biology platform. They don't sell their product, but help other companies (from pharmaceuticals to perfumes) "program" cells. They provide R&D services. This metric (loss per employee) reflects the company's massive investment in automated laboratories (foundries) and scientists.
%20in%20the%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-AI&v=1772635575217 "Chart of profit per employee (in thousands of dollars) in the market segment - AI")
Profit per employee (in thousands of dollars) for the market as a whole
Ginkgo Bioworks is a biotech platform that uses AI and robotic "foundries" to program cells and create custom microbes for industry. It's an R&D-as-a-Service. During the phase of active investment in its platform, this graph likely represents the operating loss per employee—the "cost of capital burn" for creating this unique technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772635575229 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ginkgo Bioworks Holdings (DNA)
Ginkgo Bioworks positions itself as an "organism-engineering" company, using biotechnology and AI to program cells for customers' needs. This chart demonstrates the effectiveness of its unique platform. The growth in revenue per employee reflects the increasing number of projects and the scaling of its DNA printing capabilities across various industries.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ginkgo-Bioworks-Holdings-DNA&v=1772635575255 "Sales chart per company employee Ginkgo Bioworks Holdings (DNA)")
Sales per employee in the market segment - AI
Ginkgo Bioworks (DNA) positions itself as an "organism engineer," using AI and automation to program cells (synthetic biology) for various industries. This chart shows the revenue (from R&D services) generated by each of their biologists and engineers. This allows one to assess the productivity of their high-tech platform.
Sales per employee for the market as a whole
Ginkgo Bioworks (DNA) positions itself as an "organism factory," using AI and automation to develop and program cells (such as yeast) for clients across various industries. Their business model is an R&D platform. This metric reflects how effectively their "foundries" and bioengineering staff generate service revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Ginkgo Bioworks Holdings (DNA)
Ginkgo Bioworks Holdings is a company that bills itself as an "organism engineer," using automation and AI to develop microbes for various industries. The company remains unprofitable. This chart shows strong bearish sentiment. Investors are skeptical of its business model, doubting it can ever become profitable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ginkgo-Bioworks-Holdings-DNA&v=1772635575291 "Short Shares Chart for the Company Ginkgo Bioworks Holdings (DNA)")
Shares shorted by market segment - AI
Ginkgo Bioworks is a biotech platform. They don't make drugs, but rather "program" cells (synthetic biology) for clients across various industries. This metric reflects skepticism. "Shorts" here are a bet that their business model (high factory and R&D costs) is unsustainable and unprofitable.
Shares shorted by the overall market
Ginkgo Bioworks positions itself as a "foundry" for cell engineering, leveraging AI and automation. It's a platform for other biotechs. When this chart shows rising fear, investors flee unprofitable "platform" business models. DNA's clients are having less money for R&D, which is hurting its prospects.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ginkgo Bioworks Holdings (DNA)
Ginkgo Bioworks (DNA) positions itself as an "organism engineering" company. They use their platform (laboratory "foundries") to design custom microbes for various industries (pharma, agriculture). This chart measures hype. It shows "overheated" (above 70) amid hype around synthetic biology or "oversold" (below 30) amid high losses.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ginkgo-Bioworks-Holdings-DNA&v=1772635575296 "RSI 14 indicator chart for the company's stock Ginkgo Bioworks Holdings (DNA)")
RSI 14 Market Segment - AI
Ginkgo Bioworks (DNA) is an "organism factory" (SynBio). They don't treat, but rather *engineer* microbes (on their "Foundry") for other companies (pharma, flavors). RSI_14_Seg for "AI" (in this case, SynBio) is a "hype" indicator. It helps us understand whether DNA's growth is due to their platform or the general "hype" in the sector.
RSI 14 for the overall market
Ginkgo Bioworks (DNA) is pure hype and R&D. This chart is its lifeline. During periods of market euphoria, investors are willing to "buy the dream" (cell programming) and generously fund unprofitable "growth stories." During moments of panic, investors demand real profits, and the money supply to DNA is shut off.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DNA (Ginkgo Bioworks Holdings)
Ginkgo Bioworks is an "organism foundry." They use AI and automation to engineer microbes (bacteria, yeast) for clients in the pharmaceutical, agricultural, and industrial sectors. This chart shows the average 12-month forecast of analysts. This is their collective bet on whether this futuristic business model can become profitable.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DNA-Ginkgo-Bioworks-Holdings&v=1772635575324 "A chart showing analyst consensus forecasts for the expected stock price. DNA (Ginkgo Bioworks Holdings)")
The difference between the consensus estimate and the actual stock price DNA (Ginkgo Bioworks Holdings)
Ginkgo Bioworks is a SaaS platform for biology. The company uses AI and automation (foundry) to engineer custom microbes (for example, flavor-producing yeast). It is an R&D outsourcer for pharma and industrial applications. This chart shows the difference between the consensus forecast and the price. It reflects analysts' confidence in this futuristic platform and its path to profitability.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DNA-Ginkgo-Bioworks-Holdings&v=1772635575325 "A chart showing the difference between the consensus forecast and the actual stock price. DNA (Ginkgo Bioworks Holdings)")
Analyst consensus forecast for stock prices by market segment - AI
Ginkgo Bioworks (DNA) is an "organism factory." The company uses AI and robotics to "program" cells (bacteria, yeast) to produce everything from flavors to drugs. This chart shows analysts' overall expectations for the AI sector. It reflects whether experts believe in the commercialization of synthetic biology.
Analysts' consensus forecast for the overall market share price
Ginkgo Bioworks is a microbial design company (SynBio). They're a SaaS company for biology, burning cash (R&D). This chart, which measures collective market optimism, is their risk appetite. If optimism declines (recession), investors flee speculative stocks like Ginkgo.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ginkgo Bioworks Holdings
Ginkgo Bioworks is an organism factory. They don't make products, but rather provide a platform for custom cell programming (synthetic biology) for pharmaceutical, agricultural, and industrial applications. This chart is an indicator of the bioeconomy. It likely aggregates the growth rate of their laboratory revenue and the market's faith in their long-term, venture-like business model.
AKIMA Market Segment Index - AI
Ginkgo Bioworks (DNA) is a SaaS service for biology; the company doesn't make products, but rather is an R&D platform (The Foundry) that uses AI and robots to program microbes (cells) for other companies (pharma, chemicals). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this futuristic (R&D platform) model (DNA) differentiate it from the average pharma company?
The AKIM Index for the overall market
Ginkgo Bioworks is a platform for "cell programming" (synthetic biology). The company helps clients develop new organisms for various industries. This chart, reflecting the market average, provides context. It helps assess how this ambitious but unprofitable R&D facility fits into the overall macroeconomic picture and risk appetite.
